In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of KalVista Pharmaceuticals Inc (NASDAQ: KALV) was $14.85 for the day, down -6.60% from the previous closing price of $15.9. In other words, the price has decreased by -$6.60 from its previous closing price. On the day, 1.21 million shares were traded. KALV stock price reached its highest trading level at $16.0 during the session, while it also had its lowest trading level at $14.7.
Ratios:
Our analysis of KALV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.22. In the meantime, Its Debt-to-Equity ratio is 16.62 whereas as Long-Term Debt/Eq ratio is at 16.34.
Upgrades & Downgrades
In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.
On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30.
On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 08 ’25 when Palleiko Benjamin L sold 7,294 shares for $16.51 per share. The transaction valued at 120,424 led to the insider holds 424,520 shares of the business.
Sweeny Nicole sold 3,813 shares of KALV for $51,289 on Nov 24 ’25. The Chief Commercial Officer now owns 39,728 shares after completing the transaction at $13.45 per share. On Nov 24 ’25, another insider, Piekos Brian, who serves as the Chief Financial Officer of the company, sold 4,471 shares for $13.45 each. As a result, the insider received 60,139 and left with 10,529 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 750612480 and an Enterprise Value of 724033472. For the stock, the TTM Price-to-Sale (P/S) ratio is 524.91 while its Price-to-Book (P/B) ratio in mrq is 44.15. Its current Enterprise Value per Revenue stands at 507.737 whereas that against EBITDA is -3.588.
Stock Price History:
The Beta on a monthly basis for KALV is -0.15, which has changed by 0.9653894 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $17.30, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is 14.19%, while the 200-Day Moving Average is calculated to be 15.08%.
Shares Statistics:
KALV traded an average of 1.39M shares per day over the past three months and 1813680 shares per day over the past ten days. A total of 50.54M shares are outstanding, with a floating share count of 37.77M. Insiders hold about 25.28% of the company’s shares, while institutions hold 97.71% stake in the company. Shares short for KALV as of 1764288000 were 14426123 with a Short Ratio of 10.38, compared to 1761868800 on 13328249. Therefore, it implies a Short% of Shares Outstanding of 14426123 and a Short% of Float of 32.11.
Earnings Estimates
A detailed examination of KalVista Pharmaceuticals Inc (KALV) is currently in progress, with 7 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.43 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1.65 and -$3.76 for the fiscal current year, implying an average EPS of -$3.03. EPS for the following year is -$2.09, with 8.0 analysts recommending between -$0.44 and -$2.73.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $28.33M. There is a high estimate of $39M for the next quarter, whereas the lowest estimate is $15.5M.
Based on 9 analysts’ estimates, the company’s revenue will be $120.05M in the next fiscal year. The high estimate is $242.2M and the low estimate is $33.71M.
